MUC16: The Novel Target for Tumor Therapy / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 452-459, 2022.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-939731
Biblioteca responsável:
WPRO
ABSTRACT
Mucin16 (MUC16), also known as carbohydrate antigen 125 (CA125), is a glycoprotein antigen that can be recognized by the monoclonal antibody OC125 detected from epithelial ovarian carcinoma antigen by Bast et al in 1981. CA125 is not present in normal ovarian tissue but is usually elevated in the serum of epithelial ovarian carcinoma patients. CA125 is the most commonly used serologic biomarker for the diagnosis and recurrence monitoring of epithelial ovarian carcinoma. MUC16 is highly expressed in varieties of tumors. MUC16 can interact with galectin-1/3, mesothelin, sialic acid-binding immunoglobulin-type lectins-9 (Siglec-9), and other ligands. MUC16 plays an important role in tumor genesis, proliferation, migration, invasion, and tumor immunity through various signaling pathways. Besides, therapies targeting MUC16 have some significant achievements. Related preclinical studies and clinical trials are in progress. MUC16 may be a potential novel target for tumor therapy. This article will review the mechanism of MUC16 in tumor genesis and progression, and focus on the research actuality of MUC16 in tumor therapy. This article also provides references for subsequent tumor therapy studies targeting MUC16.
.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias Ovarianas
/
Antígeno Ca-125
/
Carcinoma Epitelial do Ovário
/
Neoplasias Pulmonares
/
Proteínas de Membrana
Limite:
Feminino
/
Humanos
Idioma:
Chinês
Revista:
Chinese Journal of Lung Cancer
Ano de publicação:
2022
Tipo de documento:
Artigo